| Ytd | -27.93% | |
| 1y | -78.61% |
| Open | 0.81 | Prev Close | 0.81 | Low | 0.80 | High | 0.81 | Mkt Cap | 19.48M |
| Vol | 2.83K | Avg Vol | 157.23K | EPS | -3.26 | P/E | -0.25 | Forward P/E | -4.00 |
| Beta | 0.54 | Short Ratio | 0.36 | Inst. Own | 14.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.79 | 200-d Avg | 1.30 | 1yr Est | 2.50 |
CELU News
Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-m
Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's
On June 29, 2026, Celularity Inc. (the "Company") entered into a Loan Agreement (the "L
FLORHAM PARK, N.J. and ORLANDO, Fla.
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" o
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” o
FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”),
Company advances focused strategy, strengthens balance sheet and positions business for long-term gr
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Busines
Transaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million an
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”)
FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”
Celularity (NASDAQ: CELU - Get Free Report) and KALA BIO (NASDAQ: KALA - Get Free Report) are both s
Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is
FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”
The transaction represents the most significant milestone in the company's history.
NexGel to acquire Celularity biomaterial products, a deal expected to triple revenue to $35 million
FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”
FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”),
While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”),
FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”),
FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”),
FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”),
Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March
On Tuesday, 838 companies hit new 52-week lows.
On Wednesday, 329 companies hit new 52-week lows.
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 o